Health data is essential for our future

Data sharing leads to improved quality of healthcare, increased drug safety, better clinical and diagnostic tools, and expanded research opportunities.

Health data collected over longer periods can reveal disease patterns and trends and—when combined with artificial intelligence—enable deeper research, more accurate prediction models, and innovative treatment approaches.

Digitalization and data sharing can also enhance early disease detection by identifying potential health issues before symptoms even appear.

Roche is deeply committed to oncology, with the goal of improving the lives of people with cancer. For over 50 years, the company has been developing innovative medicines and diagnostic tools that support the prevention, early detection, diagnosis, treatment, and monitoring of cancer. The focus is on gaining a better understanding of the disease and advancing personalized healthcare.

This is why Roche has initiated several projects dedicated to researching and using health data in the context of cancer. A key initiative is the Precision Oncology Program (POP), conducted in collaboration with the University Hospital Zurich and the University of Zurich. The goal of this program is to explore how oncology patients in Switzerland can benefit from personalized datasets through the sharing and integration of health data in clinical practice.

This collaboration enables access to high-quality resources and expertise, driving the development and implementation of personalized treatment approaches. The program is based on the idea that every cancer case is unique and therefore requires a tailored, tumor-specific therapy.